FDA Accepts Pharming's Joenja sNDA Resubmission for Pediatric APDS, Sets October PDUFA Date

summarizeSummary

Pharming Group announced the FDA's acceptance of its resubmitted application for Joenja to treat children aged 4-11 with APDS, setting an October 24, 2026, PDUFA target action date.

check_boxKey Events

• FDA sNDA Resubmission Accepted

  The U.S. FDA has accepted Pharming's resubmitted Supplemental New Drug Application (sNDA) for Joenja (leniolisib) to treat children aged 4 to 11 years with Activated PI3K delta Syndrome (APDS).

• PDUFA Target Date Set

  The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026, for a decision on the sNDA.

• Addresses Prior Regulatory Setback

  This resubmission successfully addresses a Complete Response Letter (CRL) received on January 30, 2026, and follows a Type A meeting with the FDA.

• Potential Market Expansion

  If approved, Joenja would become the first approved treatment in the U.S. for this younger pediatric APDS population, expanding its existing approval for patients 12 years and older.

auto_awesomeAnalysis

The FDA's acceptance of Pharming's resubmitted sNDA for Joenja is a significant positive development, especially after the previous Complete Response Letter. This moves the company closer to expanding Joenja's market to a younger pediatric population in the U.S., which represents an unmet medical need. The assigned PDUFA date provides a clear timeline for a potential approval decision, which could further boost revenue for this already approved drug.